International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 60

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in *Cumulative List No. 12, 2007* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 60

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans la *Liste récapitulative No. 12, 2007* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 60

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran reunidas en *Cumulative List No. 12, 2007* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

adipiplonum

adipiplon — 7-{[2-(3-fluoropyridin-2-yl)-1*H*-imidazol-1-yl]methyl}-2-methyl-8-propyl[1,2,4]triazolo[1,5-*c*]pyrimidine

adipiplon — 7-{[2-(3-fluoropyridin-2-yl)-1*H*-imidazol-1-yl]méthyl}-2-méthyl-8-propyl[1,2,4]triazolo[1,5-*c*]pyrimidine

adipiplón — 7-{[2-(3-fluoropiridin-2-il)-1*H*-imidazol-1-il]metil}-2-metil-8-propil[1,2,4]triazolo[1,5-*c*]pirimidina

$C_{18}H_{18}FN_7$



agatolimodum

agatolimod — *P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-thymidine

agatolimod — *P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-thymidine

agatolimod

P-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidill-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-timidina

$C_{236}H_{303}N_{70}O_{133}P_{23}S_{23}$

DNA, d(*P*-thio)(T-C-G-T-C-G-T-T-T-T-G-T-C-G-T-T-T-T-G-T-C-G-T-T)

alacizumabum pegolum*

alacizumab pegol

immunoglobulin di-Fab' fragment, anti-[*Homo sapiens* VEGFR2 (vascular endothelial growth factor receptor 2, KDR, kinase insert domain receptor, FLK1, CD309)] pegylated humanized monoclonal antibody di-Fab' CDP791 (or g165 DFM-PEG); VH-gamma1CH1 [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.10] -*Homo sapiens* IGHG1*01 CH1-hinge (hinge PPCP12-15>AA)] (220-214')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR) [6.3.9] -*Homo sapiens* IGKC*01]; (226-bis-[maleimide-PEG (polyethylene glycol) 20 kDa]-226'')-dimer

alacizumab pégol

immunoglobuline fragment di-Fab', anti-[*Homo sapiens* VEGFR2 (récepteur 2 du facteur de croissance endothélial vasculaire, KDR, récepteur à domaine insert kinase, FLK1, CD309)] anticorps monoclonal di-Fab' humanisé pégylé CDP791 (or g165 DFM-PEG); VH-gamma1CH1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.10] -*Homo sapiens* IGHG1*01 CH1-charnière (charnière PPCP12-15>AA)] (220-214')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [6.3.9] -*Homo sapiens* IGKC*01]; dimère (226-bis-[maléimide-PEG (polyéthylène glycol) 20 kDa]-226'')

alacizumab pegol

inmunoglobulina fragmento di-Fab', anti-[*Homo sapiens* VEGFR2 (receptor 2 del factor vascular de crecimiento endotelial, KDR, receptor con dominio inserto kinasa, FLK1, CD309)] anticuerpo monoclonal di-Fab' humanizado pegilado CDP791 (o g165 DFM-PEG); VH-gamma1CH1 [VH humanizado (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.10] -*Homo sapiens* IGHG1*01 CH1-región bisagra (región bisagra PPCP12-15>AA)] (220-214')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [6.3.9] -*Homo sapiens* IGKC*01]; dímero (226-bis-[maleimida-PEG (polietilen glicol) 20 kDa]-226'')

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG  LVQPGGSLRL  SCAASGFTFS  SYGMSWVRQA  PGKGLEWVAT   50
ITSGGSYTYY  VDSVKGRFTI  SRDNAKNTLY  LQMNSLRAED  TAVYYCVRIG  100
EDALDYWGQG  TLVTVSSAST  KGPSVFPLAP  SSKSTSGGTA  ALGCLVKDYF  150
PEPVTVSWNS  GALTSGVHTF  PAVLQSSGLY  SLSSVVTVPS  SSLGTQTYIC  200
NVNHKPSNTK  VDKKVEPKSC  DKTHTCAA                           228
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS  LSASVGDRVT  ITCRASQDIA  GSLNWLQQKP  GKAIKRLIYA   50
TSSLDSGVPK  RFSGSRSGSD  YTLTISSLQP  EDFATYYCLQ  YGSFPPTFGQ  100
GTKVEIKRTV  AAPSVFIFPP  SDEQLKSGTA  SVVCLLNNFY  PREAKVQWKV  150
DNALQSGNSQ  ESVTEQDSKD  STYSLSSTLT  LSKADYEKHK  VYACEVTHQG  200
LSSPVTKSFN  RGEC                                           214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
C22 - C96; C144 - C200; C220 and light chain C214

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
Heavy chain residue C226 is the site of PEG attachment.

aleplasininum

aleplasinin — 2-{1-[(4-*tert*-butylphenyl)methyl]-5-(3-methylphenyl)-1*H*-indol-3-yl}-2-oxoacetic acid

aléplasinine — acide [1-{[4-(1,1-diméthyléthyl)phényl]méthyl}-5-(3-méthylphényl)-1*H*-indol-3-yl]oxoacétique

aleplasinina — ácido 2-{1-[(4-*terc*-butilfenil)metil]-5-(3-metilfenil)-1*H*-indol-3-il}-2-oxoacético

$C_{28}H_{27}NO_3$



almorexantum

almorexant — (2*R*)-2-[(1*S*)-6,7-dimethoxy-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-3,4-dihydroisoquinolin-2(1*H*)-yl]-*N*-methyl-2-phenylacetamide

almorexant — (2*R*)-1-[(1*S*)-6,7-diméthoxy-1-{2-[4-(trifluorométhyl)phényl]éthyl}-3,4-dihydroisoquinoléin-2(1*H*)-yl]-*N*-méthyl-2-phénylacétamide

almorexant — (2*R*)-2-[(1*S*)-6,7-dimetoxi-1-{2-[4-(trifluorometil)fenil]etil}-3,4-dihidroisoquinolin-2(1*H*)-il]-*N*-metil-2-fenilacetamida

$C_{29}H_{31}F_3N_2O_3$



amolimogenum bepiplasmidum*

amolimogene bepiplasmid	plasmid DNA vector expressing a hybrid peptide consisting of a 25 amino acid targeting signal sequence fused to the N-terminus of a 236 amino acid peptide derived from fragments of the E6 and E7 genes from HPV types 16 and 18, driven by a cytomegalovirus promoter
amolimogène bépliplasmide	vecteur constitué d'ADN plasmidique exprimant un peptide hybride composé d'une séquence signal de 25 résidus fusionnée à l'aminoacide *N*-terminal d'un peptide de 236 résidus constitué de fragments du produit des gènes E6 et E7 du Papillomavirus humain de type 16 et 18 sous contrôle d'un promoteur de cytomégalovirus
amolimogén bepiplásmido	vector formado por DNA de plásmido que expresa un péptido híbrido que consiste en una secuencia señal de 25 aminoácidos unida al extremo *N*-terminal de un péptido de 236 aminoácidos constituido por fragmentos del producto de los genes E6 y E7 del Papillomavirus humano tipos 16 y 18, controlado por un promotor de cytomegalovirus

amsilarotenum

amsilarotene	4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid
amsilarotène	acide 4-{[3,5-bis(triméthylsilyl)benzoyl]amino}benzoïque
amsilaroteno	ácido 4-{[3,5-bis(trimetilsilil)benzoil]amino}benzoico

$C_{20}H_{27}NO_3Si_2$



anacetrapibum

anacetrapib	(4*S*,5*R*)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{4'-fluoro-2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl}methyl)-4-methyl-1,3-oxazolidin-2-one
anacétrapib	(4*S*,5*R*)-5-[3,5-bis(trifluorométhyl)phényl]-3-{[4'-fluoro-2'-méthoxy-5'-(1-méthyléthyl)-4-(trifluorométhyl)biphényl-2-yl]méthyl}-4-méthyloxazolidin-2-one
anacetrapib	(4*S*,5*R*)-5-[3,5-bis(trifluorometil)fenil]-3-{[4'-fluoro-2'-metoxi-5'-(propan-2-il)-4-(trifluorometil)bifenil-2-il]metil}-4-metiloxazolidin-2-ona

$C_{30}H_{25}F_{10}NO_3$



anrukinzumabum*

anrukinzumab — immunoglobulin G1, anti-[*Homo sapiens* interleukin 13 (IL13)] humanized monoclonal IMA-638; gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR) [8.7.12] -*Homo sapiens* IGHG1*03, 97R>K (CH1 120), 117L>A (CH2 1.3), 120G>A (CH2 1] (221-218')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR) [10.3.9] -*Homo sapiens* IGKC*01]; (227-227'':230-230'')-bisdisulfide dimer

anrukinzumab — immunoglobuline G1, anti-[*Homo sapiens* interleukine 13 (IL13)] anticorps monoclonal humanisé IMA-638; chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [8.7.12] - *Homo sapiens* IGHG1*03, 97R>K (CH1 120), 117L>A (CH2 1.3), 120G>A (CH2 1]] (221-218')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [10.3.9] -*Homo sapiens* IGKC*01]; dimère (227-227'':230-230'')-bisdisulfure

anrukinzumab — inmunoglobulina G1, anti-[*Homo sapiens* interleukina 13 (IL13)] anticuerpo monoclonal humanizado IMA-638; cadena pesada gamma1 [VH humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [8.7.12] - *Homo sapiens* IGHG1*03, 97R>K (CH1 120), 117L>A (CH2 1.3), 120G>A (CH2 1]] (221-218')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [10.3.9] -*Homo sapiens* IGKC*01]; dímero (227-227'':230-230'')-bisdisulfuro

$C_{6452}H_{9954}N_{1714}O_{2024}S_{46}$

Heavy chain γ1 / Chaîne lourde γ1 / Cadena pesada γ1

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFI SYAMSWVRQA PGKGLEWVAS 50
ISSGGNTYYP DSVKGRFTIS RDNAKNSLYL QMNSLRAEDT AVYYCARLDG 100
YYFGFAYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPEALGAPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain κ / Chaîne légère κ / Cadena ligera κ

```
DIQMTQSPSS LSASVGDRVT ITCKASESVD NYGKSLMHWY QQKPGKAPKL 50'
LIYRASNLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQSNEDPW 100'
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150'
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200'
THQGLSSPVT KSFNRGEC                                    218'
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-95	22''-95''	23'-92'	23'''-92'''	138'-198'	138'''-198'''	145-201	145''-201''
218'-221	218'''-221''	227-227''	230-230''	262-322	262''-322''	368-426	368''-426''

baminerceptum*

baminercept — human tumor necrosis factor receptor superfamily member 3 (lymphotoxin-β receptor, TNF C receptor)-(2-195)-peptide (fragment of extracellular domain) fusion protein with human immunoglobulin heavy constant γ1 chain Fc fragment [227 residues, hinge (195-205) des-(1-4),C5>V, CH2 (206-315), CH3 (316-421) des-K^{107}]

baminercept — membre 3 de la superfamille des récepteurs du facteur de nécrose tumorale humain (récepteur de la lymphotoxine-β ou récepteur du TNF C)-(2-195)-peptide (fragment du domaine extracellulaire) protéine de fusion avec le fragment Fc de la chaîne lourde constante γ1 de l'immunoglobuline humaine [227 residues, dés-(1-4)-[C5>V]charnière (195-205), CH2 (206-315), des-K^{107}-CH3 (316-421)]

baminercept — miembro 3 de la superfamilia de receptores del factor de necrosis tumoral humano (receptor de la linfotoxina-β o receptor del TNF C)-(2-195)-péptido (fragmento del dominio extracelular) proteína de fusión con el fragmento Fc de la cadena pesada constante γ1 de la inmunoglobulina humana [227 restos, des(14)-[C5>V]bisagra (195-205), CH2 (206-315), desK107-CH3 (316-421)]

$C_{4074}H_{6282}N_{1134}O_{1274}S_{68}$

Monomer / Monomère / Monómero

```
AVPPYASENQ  TCRDQEKEYY  EPQHRICCSR  CPPGTYVSAK  CSRIRDTVCA   50
TCAENSYNEH  WNYLTICQLC  RPCDPVMGLE  EIAPCTSKRK  TQCRCQPGMF  100
CAAWALECTH  CELLSDCPPG  TEAELKDEVG  KGNNHCVPCK  AGHFQNTSSP  150
SARCQPHTRC  ENQGLVEAAP  GTAQSDTTCK  NPLEPLPPEM  SGTMVDKTHT  200
CPPCPAPELL  GGPSVFLFPP  KPKDTLMISR  TPEVTCVVVD  VSHEDPEVKF  250
NWYVDGVEVH  NAKTKPREEQ  YNSTYRVVSV  LTVLHQDWLN  GKEYKCKVSN  300
KALPAPIEKT  ISKAKGQPRE  PQVYTLPPSR  DELTKNQVSL  TCLVKGFYPS  350
DIAVEWESNG  QPENNYKTTP  PVLDSDGSFF  LYSKLTVDKS  RWQQGNVFSC  400
SVMHEALHNH  YTQKSLSLSP  G                                  421
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
12-27   12'-27'   28-41    28'-41'   31-49   31'-49'   52-67   52'-67'   70-85
70'-85'  73-93    73'-93'   95-101    95'-101'  108-117  108'-117'  111-136  111'-136'
139-154  139'-154'  201-201'  204-204'  236-296  236'-296'  342-400  342'-400'
```

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación

```
Asn-9   Asn-9'   Asn-146   Asn-146'   Asn-272   Asn-272'
```

bentamapimodum

bentamapimod — 2-(1,3-benzothiazol-2-yl)-2-[2-({4-[(morpholin-4-yl)methyl]phenyl}=methoxy)pyrimidin-4-yl]acetonitrile

bentamapimod — (benzothiazol-2-yl)[2-({4-[(morpholin-4-yl)méthyl]phényl}=méthoxy)pyrimidin-4-yl]acétonitrile

bentamapimod — 2-(1,3-benzotiazol-2-il)-2-[2-({4-[(morfolin-4-il)metil]fenil}metoxi)=pirimidin-4-il]acetonitrilo

$C_{25}H_{23}N_5O_2S$



and enantiomer
et énantiomère
y enantiómero

berubicinum

berubicin — (8*S*,10*S*)-10-[(3-amino-4-*O*-benzyl-2,3,6-trideoxy-α-L-*lyxo*-hexopyranosyl)oxy]-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione

bérubicine — (8*S*,10*S*)-10-[(3-amino-4-*O*-benzyl-2,3,6-tridéoxy-α-L-*lyxo*-hexopyranosyl)oxy]-7,8,9,10-tétrahydro-6,8,11-trihydroxy-8-(hydroxyacétyl)-1-méthoxytétracène-5,12-dione

berubicina — (8*S*,10*S*)-10-[(3-amino-4-*O*-bencil-2,3,6-tridesoxi-α-L-*lixo*-hexopiranosil)oxi]- 6,8,11-trihidroxi-8-(hidroxiacetil)-1-metoxi-7,8,9,10-tetrahidrotetraceno-5,12-diona

$C_{34}H_{35}NO_{11}$



besifloxacinum

besifloxacin — 7-[(3*R*)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

bésifloxacine — (+)-acide 7-[(3*R*)-3-aminohexahydro-1*H*-azépin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoléine-3-carboxylique

besifloxacino — ácido 7-[(3*R*)-3-aminoazepan-1-il]-1-ciclopropil-8-cloro-6-fluoro-4-oxo-1,4-dihidroquinolina-3-carboxílico

$C_{19}H_{21}ClFN_3O_3$



betrixabanum

betrixaban — *N*-(5-chloropyridin-2-yl)-2-[4-(*N*,*N*-dimethylcarbamimidoyl)benzamido]-5-methoxybenzamide

bétrixaban — *N*-(5-chloropyridin-2-yl)-2-({4-[(diméthylamino)iminométhyl]benzoyl}amino)-5-méthoxybenzamide

betrixabán — *N*-(5-cloropiridin-2-il)-2-[4-(*N*,*N*-dimetilcarbamimidoil)benzamido]-5-metoxibenzamida

$C_{23}H_{22}ClN_5O_3$



briobaceptum*

briobacept — aspartyl[1-valine,20-asparagine,27-proline](human tumor necrosis factor receptor superfamily member 13C (BAFF receptor, BlyS receptor 3 or CD268 antigen)-(1-71)-peptidyl (part of the extracellular domain))valyl(human immunoglobulin G1 Fc fragment, *Homo sapiens* IGHG1-(104-329)-peptide) (79-79':82-82')-bisdisulfide dimer

briobacept — aspartyl[1-valine,20-asparagine,27-proline](membre 13C de la superfamille des récepteurs du facteur de nécrose tumorale humain (récepteur du BAFF, récepteur 3 du BlyS ou antigène CD268)-(1-71)-peptidyl (fragment du domaine extracellulaire))valyl(fragment Fc de l'immunoglobuline G1 humaine, *Homo sapiens* IGHG1-(104-329)-peptide) (79-79':82-82')-bisdisulfure du dimère

briobacept — aspartill[1-valina,20-asparagina,27-prolina](miembro 13C de la superfamilia de receptores del factor de necrosis tumoral humano (receptor del BAFF, receptor 3 del BlyS o antígeno CD268)-(1-71)-peptidil (fragmento del dominio extracelular))valil(fragmento Fc de la inmunoglobulina G1 humana, *Homo sapiens* IGHG1-(104-329)-péptido) (79-79':82-82')-bisdisulfuro del dímero

$C_{2910}H_{4542}N_{814}O_{878}S_{24}$

Monomer / Monomère / Monómero

```
DVRRGPRSLR  GRDAPAPTPC  NPAECFDPLV  RHCVACGLLR  TPRPKPAGAS   50
SPAPRTALQP  QESVGAGAGE  AAVDKTHTCP  PCPAPELLGG  PSVFLFPPKP  100
KDTLMISRTP  EVTCVVVDVS  HEDPEVKFNW  YVDGVEVHNA  KTKPREEQYN  150
STYRVVSVLT  VLHQDWLNGK  EYKCKVSNKA  LPAPIEKTIS  KAKGQPREPQ  200
VYTLPPSRDE  LTKNQVSLTC  LVKGFYPSDI  AVEWESNGQP  ENNYKTTPPV  250
LDSDGSFFLY  SKLTVDKSRW  QQGNVFSCSV  MHEALHNHYT  QKSLSLSPG   249
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

20-33 20'-33' 25-36 25'-36' 79-79' 82-82' 114-174 114'-174' 220-278 220'-278'

cabazitaxelum

cabazitaxel — 1-hydroxy-7β,10β-dimethoxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-[(2*R*,3*S*)-3-{[(*tert*-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate]

cabazitaxel — (-)-12b-acétate 12-benzoate et 9-[(2*R*,3*S*)-3-{[(1,1-diméthyléthoxy)carbonyl]amino}-2-hydroxy-3-phénylpropanoate] de (2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-11-hydroxy-4,6-diméthoxy-4a,8,13,13-tétraméthyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-décahydro-7,11-méthano-1*H*-cyclodéca[3,4]benzo[1,2-*b*]oxète-9,12,12b(2a*H*)-triyle

cabazitaxel — 4-acetato 2-benzoato 13-[(2*R*,3*S*)-3-{[(*terc*-butoxi)carbonil]amino}-2-hidroxipropanoato] de 1-hidroxi-7β,10β-dimetoxi-9-oxo-5β,20-epoxitax-11-eno-2α,4,13α-triil

$C_{45}H_{57}NO_{14}$



cariprazinum

cariprazine	3-(*trans*-4-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}cyclohexyl)-1,1-dimethylurea
cariprazine	*N'*-(*trans*-4-{2-[4-(2,3-dichlorophényl)pipérazin-1-yl]éthyl}cyclohexyl)-*N*,*N*-diméthylurée
cariprazina	*N'*-(*trans*-4-{2-[4-(2,3-diclorofenil)piperazin-1-il]etil}ciclohexil)-*N*,*N*-dimetilurea

$C_{21}H_{32}Cl_2N_4O$



carmegliptinum

carmegliptin	(4*S*)-1-{(2*S*,3*S*,11b*S*)-2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2*H*-benzo[*a*]quinolizin-3-yl}-4-(fluoromethyl)pyrrolidin-2-one
carmégliptine	(4*S*)-1-[(2*S*,3*S*,11b*S*)-2-amino-9,10-diméthoxy-1,3,4,6,7,11b-hexahydro-2*H*-pyrido[2,1-*a*]isoquinoléin-3-yl]-4-(fluorométhyl)=pyrrolidin-2-one
carmegliptina	(4*S*)-1-{(2*S*,3*S*,11b*S*)-2-amino-9,10-dimetoxi-1,3,4,6,7,11b-hexahidro-2*H*-benzo[*a*]quinolizin-3-il}-4-(fluorometil)pirrolidin-2-ona

$C_{20}H_{28}FN_3O_3$



cobiprostonum

cobiprostone — 7-{(2*R*,4a*R*,5*R*,7a*R*)-2-[(3*S*)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxooctahydrocyclopenta[*b*]pyran-5-yl}heptanoic acid

cobiprostone — acide 7-{(2*R*,4a*R*,5*R*,7a*R*)-2-[(3*S*)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxooctahydrocyclopenta[*b*]pyran-5-yl}heptanoïque

cobiprostona — ácido 7-{(2*R*,4a*R*,5*R*,7a*R*)-2-[(3*S*)-1,1-difluoro-3-metilpentil]-2-hidroxi-6-oxooctahidrociclopenta[*b*]piran-5-il}heptanoico

$C_{21}H_{34}F_2O_5$



conestatum alfa*

conestat alfa — human plasma protease C1 inhibitor (C1 esterase inhibitor) (*N*,*O*-glycosylated recombinant protein expressed in the mammary gland of transgenic rabbits), glycoform α

conestat alfa — inhibiteur de la protéase plasmatique C1 humain (inhibiteur de l'esterase C1) (protéine *N*,*O*-glycosylée recombinante exprimée dans la glande mammaire de lapines transgéniques), glycoforme α

conestat alfa — inhibidor de la proteasa plasmática C1 humana (inhibidor de la esterasa C1) (proteína *N*,*O*-glicosilada recombinante expresada en glándula mamaria de coneja transgénica), glicoforma α

$C_{2355}H_{3745}N_{613}O_{728}S_{17}$

```
NPNATSSSSQ  DPESLQDRGE  GKVATTVISK  MLFVEPILEV  SSLPTTNSTT   50
NSATKITANT  TDEPTTQPTT  EPTTQPTIQP  TQPTTQLPTD  SPTQPTTGSF  100
CPGPVTLCSD  LESHSTEAVL  GDALVDFSLK  LYHAFSAMKK  VETNMAFSPF  150
SIASLLTQVL  LGAGENTKTN  LESILSYPKD  FTCVHQALKG  FTTKGVTSVS  200
QIFHSPDLAI  RDTFVNASRT  LYSSSPRVLS  NNSDANLELI  NTWVAKNTNN  250
KISRLLDSLP  SDTRLVLLNA  IYLSAKWKTT  FDPKKTRMEP  FHFKNSVIKV  300
PMMNSKKYPV  AHFIDQTLKA  KVGQLQLSHN  LSLVILVPQN  LKHRLEDMEQ  350
ALSPSVFKAI  MEKLEMSKFQ  PTLLTLPRIK  VTTSQDMLSI  MEKLEFFDFS  400
YDLNLCGLTE  DPDLQVSAMQ  HQTVLELTET  GVEAAAASAI  SVARTLLVFE  450
VQQPFLFVLW  DQQHKFPVFM  GRVYDPRA                           478
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
101-406 108-183

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
Asn-3 Thr-26 Ser-42 Asn-47 Thr-49 Asn-59 Thr-61
Thr-66 Thr-70 Thr-74 Asn-216 Asn-231 Asn-250 Asn-330

dacetuzumabum*

dacetuzumab — immunoglobulin G1, anti-[*Homo sapiens* CD40 (TNF receptor superfamily member 5, TNFRSF5)] humanized monoclonal SGN-40 (or huS2C6); gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.7] -*Homo sapiens* IGHG1*03, 97R>K (CH1 120)] (217-219')-disulfide with kappa light chain humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC*01]; (223-223'':226-226'')-bisdisulfide dimer

dacétuzumab — immunoglobuline G1, anti-[*Homo sapiens* CD40 (membre 5 de la superfamille des récepteurs du TNF, TNFRSF5)] anticorps monoclonal humanisé SGN-40 (ou huS2C6); chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.7] - *Homo sapiens* IGHG1*03, 97R>K (CH1 120)] (217-219')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC*01]; dimère (223-223'':226-226'')-bisdisulfure

dacetuzumab — inmunoglobulina G1, anti-[*Homo sapiens* CD40 (miembro 5 de la superfamilia de receptores del TNF, TNFRSF5)] anticuerpo monoclonal humanizado SGN-40 (o huS2C6); cadena pesada gamma1 [VH humanizado (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.7] - *Homo sapiens* IGHG1*03, 97R>K (CH1 120)] (217-219')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC*01]; dímero (223-223'':226-226'')-bisdisulfuro

$C_{6452}H_{9964}N_{1732}O_{1998}S_{42}$

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG  LVQPGGSLRL  SCAASGYSFT  GYYIHWVRQA  PGKGLEWVAR   50
VIPNAGGTSY  NQKFKGRFTL  SVDNSKNTAY  LQMNSLRAED  TAVYYCAREG  100
IYWWGQGTLV  TVSSASTKGP  SVFPLAPSSK  STSGGTAALG  CLVKDYFPEP  150
VTVSWNSGAL  TSGVHTFPAV  LQSSGLYSLS  SVVTVPSSSL  GTQTYICNVN  200
HKPSNTKVDK  KVEPKSCDKT  HTCPPCPAPE  LLGGPSVFLF  PPKPKDTLMI  250
SRTPEVTCVV  VDVSHEDPEV  KFNWYVDGVE  VHNAKTKPRE  EQYNSTYRVV  300
SVLTVLHQDW  LNGKEYKCKV  SNKALPAPIE  KTISKAKGQP  REPQVYTLPP  350
SREEMTKNQV  SLTCLVKGFY  PSDIAVEWES  NGQPENNYKT  TPPVLDSDGS  400
FFLYSKLTVD  KSRWQQGNVF  SCSVMHEALH  NHYTQKSLSL  SPGK        444
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS  LSASVGDRVT  ITCRSSQSLV  HSNGNTFLHW  YQQKPGKAPK   50'
LLIYTVSNRF  SGVPSRFSGS  GSGTDFTLTI  SSLQPEDFAT  YFCSQTTHVP  100'
WTFGQGTKVE  IKRTVAAPSV  FIFPPSDEQL  KSGTASVVCL  LNNFYPREAK  150'
VQWKVDNALQ  SGNSQESVTE  QDSKDSTYSL  SSTLTLSKAD  YEKHKVYACE  200'
VTHQGLSSPV  TKSFNRGEC                                      219'
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
22-96    22"-96"    23'-93'    23'"-93'"   139'-199'  139'"-199'"  141-197  141"-197"
217-219' 217"-219'" 223-223"   226-226"    258-318    258"-318"    364-422  364"-422"
```

daporinadum

daporinad — *(2E)-N*-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide

daporinad — (2*E*)-*N*-[4-(1-benzoylpipéridin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-énamide

daporinad — (2*E*)-*N*-[4-(1-benzoilpiperidin-4-il)butil]-3-(piridin-3-il)prop-2-enamida

$C_{24}H_{29}N_3O_2$



darinaparsinum

darinaparsin — L-γ-glutamyl-*S*-(dimethylarsanyl)-L-cysteinylglycine

darinaparsine — L-γ-glutamyl-*S*-(diméthylarsanyl)-L-cystéinylglycine

darinaparsina — L-γ-glutamil-*S*-(dimetilarsanil)-L-cisteinilglicina

$C_{12}H_{22}AsN_3O_6S$



dexnebivololum

dexnebivolol — (1*R*)-2-({(2*R*)-2-[(2*S*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]-2-hydroxyethyl}amino)-1-[(2*R*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]ethanol

dexnébivolol — (1*R*,1'*R*)-1,1'-[(2*R*,2'*S*)-bis(6-fluoro-3,4-dihydro-2*H*-1-benzopyran-2-yl)]-2,2'-azanediyldiéthanol

dexnebivolol — (1*R*)-2-({(2*R*)-2-[(2*S*)-6-fluoro-3,4-dihidro-2*H*-cromen-2-il]-2-hidroxietil}amino)-1-[(2*R*)-6-fluoro-3,4-dihidro-2*H*-cromen-2-il]etanol

$C_{22}H_{25}F_2NO_4$



emricasanum

emricasan — (3*S*)-3-{(2*S*)-2-[*N*-(2-*tert*-butylphenyl)oxamoylamino]propanamido}-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid

emricasan — acide (3*S*)-3-({(2*S*)-2-[({[2-(1,1-diméthyléthyl)phényl]amino}=oxoacétyl)amino]propanoyl}amino)-4-oxo-5-(2,3,5,6-tétrafluorophénoxy)pentanoïque

emricasán — ácido (3*S*)-3-{(2*S*)-2-[*N*-(2-*terc*-butilfenil)oxamoilamino]=propanamido}-4-oxo-5-(2,3,5,6-tetrafluorofenoxi)pentanoico

$C_{26}H_{27}F_4N_3O_7$



eribaxaban

eribaxaban (2*R*,4*R*)- N^1-(4-chlorophenyl)- N^2-[2-fluoro-4-(2-oxopyridin-1(2*H*)-yl)phenyl]-4-methoxypyrrolidine-1,2-dicarboxamide

éribaxaban (2*R*,4*R*)-N^1-(4-chlorophényl)-N^2-[2-fluoro-4-(2-oxopyridin-1(2*H*)-yl)phényl]-4-méthoxypyrrolidine-1,2-dicarboxamide

eribaxabán (2*R*,4*R*)- N^1-(4-clorofenil)- N^2-[2-fluoro-4-(2-oxopiridin-1(2*H*)-il)fenil]-4-metoxipirrolidina-1,2-dicarboxamida

$C_{24}H_{22}ClFN_4O_4$



ezatiostatum

ezatiostat ethyl [(4*S*)-4-amino-5-ethoxy-5-oxopentanoyl]-*S*-benzyl-L-cysteinyl-D-2-phenylglycinate

ézatiostat (2*R*)-[(4*S*)-4-amino-5-éthoxy-5-oxopentanoyl]-*S*-benzyl-L-cystéinyl-2-phénylglycinate d'éthyle

ezatiostat (2*R*)-[(4*S*)-4-amino-5-etoxi-5-oxopentanoil]-*S*-bencil-L-cisteinil-2-fenilglicinato de etilo

$C_{27}H_{35}N_3O_6S$



fasobegronum

fasobegron 4'-(2-{[(2*R*)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)-3-methoxy-[1,1'-biphenyl]-4-carboxylic acid

fasobégron acide 4'-(2-{[(2*R*)-2-(3-chlorophényl)-2-hydroxyéthyl]amino}éthyl)-3-méthoxybiphényle-4-carboxylique

fasobegrón ácido 4'-(2-{[(2*R*)-2-(3-clorofenil)-2-hidroxietil]amino}etil)-[1,1'-bifenil]-3-metoxi-4-carboxílico

$C_{24}H_{24}ClNO_4$



favipiravirum

favipiravir — 6-fluoro-3-hydroxypyrazine-2-carboxamide

favipiravir — 6-fluoro-3-hydroxypyrazine-2-carboxamide

favipiravir — 6-fluoro-3-hidroxipirazina-2-carboxamida

$C_5H_4FN_3O_2$



fermagatum

fermagate — diiron(III) tetramagnesium carbonate dodecahydroxide—water (1/4)

fermagate — tétrahydrate de carbonate et bis[(*OC*-6-11)-hexahydroxyferrate(3$^-$)] de tétramagnésium

fermagato — dodecahidróxidocarbonato de dihierro(III) y tetramagnesio—agua(1/4)

$CH_{12}Fe_2Mg_4O_{15} \cdot 4\ H_2O$



flopristinum

flopristin — (3*R*,4*R*,5*E*,10*E*,12*E*,14*S*,16*R*,26a*R*)-16-fluoro-14-hydroxy-4,12-dimethyl-3-(propan-2-yl)-3,4,8,9,14,15,16,17,24,25,26,26a-dodecahydro-1*H*,7*H*,22*H*-21,18-azenopyrrolo=[2,1-*c*][1,8,4,19]dioxadiazacyclotetracosine-1,7,22-trione

flopristine — (3*R*,4*R*,5*E*,10*E*,12*E*,14*S*,16*R*,26a*R*)-16-fluoro-14-hydroxy-4,12-diméthyl-3-(1-méthyléthyl)-8,9,14,15,16,17,24,25,26,26a-décahydro-3*H*-21,18-nitrilo-1*H*,22*H*-pyrrolo=[2,1-*c*][1,8,4,19]dioxadiazacyclotétracosine-1,7,22(4*H*)-trione

flopristina — (3*R*,4*R*,5*E*,10*E*,12*E*,14*S*,16*R*,26a*R*)-16-fluoro-14-hidroxi-4,12-dimetil-3-(propan-2-il)-3,4,8,9,14,15,16,17,24,25,26,26a-dodecahidro-1*H*,7*H*,22*H*-21,18-azenopirrolo=[2,1-*c*][1,8,4,19]dioxadiazaciclotetracosina-1,7,22-triona

$C_{28}H_{38}FN_3O_6$



folitixorinum

folitixorin — *N*-{4-[(6a*RS*)-3-amino-1-oxo-1,4,5,6,6a,7-hexahydroimidazo=[1,5-*f*]pteridin-8(9*H*)-yl]benzoyl}-L-glutamic acid

folitixorine — acide *N*-{4-[(6a*RS*)-3-amino-1-oxo-1,4,5,6,6a,7-hexahydroimidazo[1,5-*f*]ptéridin-8(9*H*)-yl]benzoyl}-L-glutamique

folitixorina — ácido *N*-{4-[(6a*RS*)-3-amino-1-oxo-1,4,5,6,6a,7-hexahidroimidazo[1,5-*f*]pteridin-8(9*H*)-il]benzoil}-L-glutámico

$C_{20}H_{23}N_7O_6$



and epimer at C*
et l'épimère en C*
y el epímero al C*

ibodutantum

ibodutant — 6-methyl-*N*-{1-[({(1*R*)-1-[({1-[(tetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl}methyl)amino]-3-phenyl-1-oxopropan-2-yl}amino)carbonyl]cyclopentyl}-1-benzothiophene-2-carboxamide

ibodutant — *N*-[1-({(1*R*)-1-benzyl-2-oxo-2-[({1-[(tétrahydro-2*H*-pyran-4-yl)méthyl]pipéridin-4-yl}méthyl)amino]éthyl}carbamoyl)cyclopentyl]-6-méthyl-1-benzothiophène-2-carboxamide

ibodutant — *N*-[1-({(1*R*)-1-bencil-2-oxo-2-[({1-[(tetrahidro-2*H*-piran-4-il)metil]piperidin-4-il}metil)amino]etil}carbamoil)ciclopentil]-6-metil-1-benzotiofeno-2-carboxamida

$C_{37}H_{48}N_4O_4S$



imegliminum

imeglimin — (4*R*)-6-(dimethylamino)-4-methyl-4,5-dihydro-1,3,5-triazin-2-amine

iméglimine — (+)-(6*R*)-1,6-dihydro-*N*,*N*,6-triméthyl-1,3,5-triazine-2,4-diamine

imeglimina — (4*R*)-6-(dimetilamino)-4-metil-4,5-dihidro-1,3,5-triazin-2-amina

$C_6H_{13}N_5$



laromustinum

laromustine — 2-(2-chloroethyl)-1,2-bis(methanesulfonyl)-*N*-methylhydrazinecarboxamide

laromustine — 2'-(2-chloroéthyl)-*N*-méthyl-1',2'-bis(méthylsulfonyl)=carbamohydrazide

laromustina — 2-(2-cloroetil)-1,2-bis(metanosulfonil)-*N*-metilhidrazinacarboxamida

$C_6H_{14}ClN_3O_5S_2$



levonebivololum

levonebivolol — (1*S*)-2-({(2*S*)-2-[(2*R*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]-2-hydroxyethyl}amino)-1-[(2*S*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]ethanol

lévonébivolol — (1*S*,1'*S*)-1,1'-[(2*R*,2'*S*)-bis(6-fluoro-3,4-dihydro-2*H*-1-benzopyran-2-yl)]-2,2'-azanediyldiéthanol

levonebivolol — (1*S*)-2-({(2*S*)-2-[(2*R*)-6-fluoro-3,4-dihidro-2*H*-cromen-2-il]-2-hidroxietil}amino)-1-[(2*S*)-6-fluoro-3,4-dihidro-2*H*-cromen-2-il]etanol

$C_{22}H_{25}F_2NO_4$



linopristinum

linopristin — *N*-{(6*R*,9*S*,10*R*,13*S*,15a*S*,22*S*,24a*S*)-22-{[4-(dimethylamino)phenyl]methyl}-6-ethyl-10,23-dimethyl-18-[(morpholin-4-yl)methyl]-5,8,12,15,21,24-hexaoxo-13-phenyl-1,2,3,5,6,7,8,9,10,11,12,13,14,15,15a,16,19,21,22,23,24,24a-docosahydropyrido[2,1-*f*]pyrrolo[2,1-*l*][1,4,7,10,13,16]=oxapentaazacyclononadecin-9-yl}-3-hydroxypyridine-2-carboxamide

linopristine — (6*R*,9*S*,10*R*,13*S*,15a*S*,22*S*,24a*S*)-22-{[4-(diméthylamino)=phényl]méthyl}-6-éthyl-9-{[(3-hydroxypyridin-2-yl)carbonyl]amino}-10,23-diméthyl-18-[(morpholin-4-yl)méthyl]-13-phényl-1,2,3,6,7,9,10,13,14,16,19,22,23,24a-tétradécahydro-12*H*-pyrido[2,1-*f*]pyrrolo[2,1-*l*][1,4,7,10,13,16]=oxapentaazacyclononadécine-5,8,12,15,21,24(15a*H*)-hexone

linopristina — *N*-{(6*R*,9*S*,10*R*,13*S*,15a*S*,22*S*,24a*S*)-22-{[4-(dimetilamino)fenil]=metil}-6-etil-13-fenil-10,23-dimetil-18-[(morfolin-4-il)metil]-5,8,12,15,21,24-hexaoxo-1,2,3,5,6,7,8,9,10,11,12,13,14,15,15a,16,19,21,22,23,24,24a-docosahidropirido[2,1-*f*]pirrolo[2,1-*l*][1,4,7,10,13,16]=oxapentaazaciclononadecin-9-il}-3-hidroxipiridina-2-carboxamida

$C_{50}H_{63}N_9O_{10}$



lucatumumabum*

lucatumumab — immunoglobulin G1, anti-[*Homo sapiens* CD40 (TNF receptor superfamily member 5, TNFRSF5)] human monoclonal antibody CHIR-12.12; gamma1 heavy chain [*Homo sapiens* VH [8.8.13] -IGHG1*03 (CH1 S10>A), no C-terminal lysine] from clone CHIR-12.12 (223-219')-disulfide with kappa light chain [*Homo sapiens* V-KAPPA (IGKV2-28-IGJK3*01, K12>R) [11.3.9] -IGKC*01] from clone CHIR-12.12; (229-229":232-232")-bisdisulfide dimer

lucatumumab — immunoglobuline G1, anti-[*Homo sapiens* CD40 (membre 5 de la superfamille des récepteurs du TNF, TNFRSF5)] anticorps monoclonal humain CHIR-12.12; chaîne lourde gamma1 [*Homo sapiens* VH [8.8.13] -IGHG1*03 (CH1 S10>A), pas de lysine C-terminale] du clone CHIR-12.12 (223-219')-disulfure avec la chaîne légère kappa [*Homo sapiens* V-KAPPA (IGKV2-28-IGJK3*01, K12>R) [11.3.9] -IGKC*01] du clone CHIR-12.12; dimère (229-229":232-232")-bisdisulfure

lucatumumab — inmunoglobulina G1, anti-[*Homo sapiens* CD40 (miembro 5 de la superfamilia de receptores del TNF, TNFRSF5)] anticuerpo monoclonal humano CHIR-12.12; cadena pesada gamma1 [*Homo sapiens* VH [8.8.13] -IGHG1*03 (CH1 S10>A), sin lisina C-terminal] del clon CHIR-12.12 (223-219')-disulfuro con la cadena ligera kappa [*Homo sapiens* V-KAPPA (IGKV2-28-IGJK3*01, K12>R) [11.3.9] -IGKC*01] del clon CHIR-12.12; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG  VVQPGRSLRL  SCAASGFTFS  SYGMHWVRQA  PGKGLEWVAV   50
ISYEESNRYH  ADSVKGRFTI  SRDNSKITLY  LQMNSLRTED  TAVYYCARDG  100
GIAAPGPDYW  GQGTLVTVSS  ASTKGPSVFP  LAPASKSTSG  GTAALGCLVK  150
DYFPEPVTVS  WNSGALTSGV  HTFPAVLQSS  GLYSLSSVVT  VPSSSLGTQT  200
YICNVNHKPS  NTKVDKRVEP  KSCDKTHTCP  PCPAPELLGG  PSVFLFPPKP  250
KDTLMISRTP  EVTCVVVDVS  HEDPEVKFNW  YVDGVEVHNA  KTKPREEQYN  300
STYRVVSVLT  VLHQDWLNGK  EYKCKVSNKA  LPAPIEKTIS  KAKGQPREPQ  350
VYTLPPSREE  MTKNQVSLTC  LVKGFYPSDI  AVEWESNGQP  ENNYKTTPPV  400
LDSDGSFFLY  SKLTVDKSRW  QQGNVFSCSV  MHEALHNHYT  QKSLSLSPGK  450
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPLS  LTVTPGEPAS  ISCRSSQSLL  YSNGYNYLDW  YLQKPGQSPQ   50
VLISLGSNRA  SGVPDRFSGS  GSGTDFTLKI  SRVEAEDVGV  YYCMQARQTP  100
FTFGPGTKVD  IRRTVAAPSV  FIFPPSDEQL  KSGTASVVCL  LNNFYPREAK  150
VQWKVDNALQ  SGNSQESVTE  QDSKDSTYSL  SSTLTLSKAD  YEKHKVYACE  200
VTHQGLSSPV  TKSFNRGEC                                      219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Light Chain Intrachain: C23-C93, C149-C199
Heavy Chain Intrachain: C22-C96, C147-C203, C264-C324, C369-C428
Interchain: Light Chain: C219-Heavy Chain 223, Heavy Chain 1 C229-Heavy Chain 2 C229, Heavy Chain 1 C232 - Heavy Chain 2 C232

milatuzumabum*

milatuzumab — immunoglobulin G1, anti-[*Homo sapiens* CD74 (major histocompatibility complex class II invariant chain)] humanized monoclonal IMMU-115 (or hLL1); gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.13] -*Homo sapiens* IGHG1*03] (223-219')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC*01]; (229-229'':232-232'')-bisdisulfide dimer

milatuzumab — immunoglobuline G1, anti-[*Homo sapiens* CD74 (chaîne invariante du complexe majeur d'histocompatibilité de classe II)] anticorps monoclonal humanisé IMMU-115 (ou hLL1); chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.13] -*Homo sapiens* IGHG1*03] (223-219')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC*01]; dimère (229-229'':232-232'')-bisdisulfure

milatuzumab — inmunoglobulina G1, anti-[*Homo sapiens* CD74 (cadena invariable del complejo mayor de histocompatibilidad de clase II)] anticuerpo monoclonal humanizado IMMU-115 (o hLL1); cadena pesada gamma1 [VH humanizado (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.13] - *Homo sapiens* IGHG1*03] (223-219')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC*01]; dímero (229-229'':232-232'')-bisdisulfuro

$C_{6518}H_{10066}N_{1758}O_{2020}S_{40}$

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGSE  LKKPGASVKV  SCKASGYTFT  NYGVNWIKQA  PGQGLQWMGW  50
INPNTGEPTF  DDDFKGRFAF  SLDTSVSTAY  LQISSLKADD  TAVYFCSRSR  100
GKNEAWFAYW  GQGTLVTVSS  ASTKGPSVFP  LAPSSKSTSG  GTAALGCLVK  150
DYFPEPVTVS  WNSGALTSGV  HTFPAVLQSS  GLYSLSSVVT  VPSSSLGTQT  200
YICNVNHKPS  NTKVDKRVEP  KSCDKTHTCP  PCPAPELLGG  PSVFLFPPKP  250
KDTLMISRTP  EVTCVVVDVS  HEDPEVKFNW  YVDGVEVHNA  KTKPREEQYN  300
STYRVVSVLT  VLHQDWLNGK  EYKCKVSNKA  LPAPIEKTIS  KAKGQPREPQ  350
VYTLPPSREE  MTKNQVSLTC  LVKGFYPSDI  AVEWESNGQP  ENNYKTTPPV  400
LDSDGSFFLY  SKLTVDKSRW  QQGNVFSCSV  MHEALHNHYT  QKSLSLSPGK  450
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPLS  LPVTLGQPAS  ISCRSSQSLV  HRNGNTYLHW  FQQRPGQSPR  50'
LLIYTVSNRF  SGVPDRFSGS  GSGTDFTLKI  SRVEAEDVGV  YFCSQSSHVP  100'
PTFGAGTRLE  IKRTVAAPSV  FIFPPSDEQL  KSGTASVVCL  LNNFYPREAK  150'
VQWKVDNALQ  SGNSQESVTE  QDSKDSTYSL  SSTLTLSKAD  YEKHKVYACE  200'
VTHQGLSSPV  TKSFNRGEC                                      219'
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
22-96    22"-96"    23'-93'    23'"-93'"   139'-199'  139'"-199'"  147-203  147"-203"
219'-223 219'"-223" 229-229"   232-232"    264-324    264"-324"    370-428  370"-428"
```

mirabegronum

mirabegron — 2-(2-amino-1,3-thiazol-4-yl)-*N*-[4-(2-{[(2*R*)-2-hydroxy-2-phenylethyl]=amino}ethyl)phenyl]acetamide

mirabégron — 2-(2-aminothiazol-4-yl)-*N*-[4-(2-{[(2*R*)-2-hydroxy-2-phényléthyl]=amino}éthyl)phényl]acétamide

mirabegrón — 2-(2-amino-1,3-tiazol-4-il)-*N*-[4-(2-{[(2*R*)-2-fenil-2-hidroxietil]amino}=etil)fenil]acetamida

$C_{21}H_{24}N_4O_2S$



monepantelum

monepantel — *N*-{2-cyano-1-[(2*S*)-5-cyano-2-(trifluoromethyl)phenoxy]propan-2-yl}-4-(trifluoromethylsulfanyl)benzamide

monépantel — *N*-{(1*S*)-1-cyano-2-[5-cyano-2-(trifluorométhyl)-1-méthylphénoxy]-4-[(trifluorométhyl)sulfanyl]benzamide

monepantel — *N*-{2-ciano-1-[(2*S*)-5-ciano-2-(trifluorometil)fenoxi]propan-2-il}-4-(trifluorometilsulfanil)benzamida

$C_{20}H_{13}F_6N_3O_2S$



nelivaptanum

nelivaptan — (2*S*,4*R*)-1-{(3*R*)-5-chloro-1-[(2,4-dimethoxybenzene)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1*H*-indol-3-yl}-4-hydroxy-*N*,*N*-dimethylpyrrolidine-2-carboxamide

nélivaptan — (2*S*,4*R*)-1-{(3*R*)-5-chloro-1-[(2,4-diméthoxyphényl)sulfonyl]-3-(2-méthoxyphényl)-2-oxo-2,3-dihydro-1*H*-indol-3-yl}-4-hydroxy-*N*,*N*-diméthylpyrrolidine-2-carboxamide

nelivaptán — (2*S*,4*R*)-1-{(3*R*)-5-cloro-1-[(2,4-dimetoxibenceno)sulfonil]-3-(2-metoxifenil)-2-oxo-2,3-dihidro-1*H*-indol-3-il}-4-hidroxi-*N*,*N*-dimetilpirrolidina-2-carboxamida

$C_{30}H_{32}ClN_3O_8S$



nesbuvirum

nesbuvir — 5-cyclopropyl-2-(4-fluorophenyl)-6-[*N*-(2-hydroxyethyl)=methanesulfonamido]-*N*-methyl-1-benzofuran-3-carboxamide

nesbuvir — 5-cyclopropyl-2-(4-fluorophényl)-6-[(2-hydroxyéthyl)(méthylsulfonyl)=amino]-*N*-méthyl-1-benzofurane-3-carboxamide

nesbuvir — 5-ciclopropil-2-(4-fluorofenil)-6-[*N*-(2-hidroxietil)metanosulfonamido]-*N*-metil-1-benzofuran-3-carboxamida

$C_{22}H_{23}FN_2O_5S$



odanacatibum

odanacatib	(2*S*)-*N*-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-{[(1*S*)-2,2,2-trifluoro-1-{4'-(methanesulfonyl)-[1,1'-biphenyl]-4-yl}ethyl]amino}= pentanamide
odanacatib	(2*S*)-*N*-(1-cyanocyclopropyl)-4-fluoro-4-méthyl-2-({(1*S*)-2,2,2-trifluoro-1-[4'-(méthylsulfonyl)biphényl-4-yl]éthyl}amino)pentanamide
odanacatib	(2*S*)-*N*-(1-cianociclopropil)-4-fluoro-4-metil-2-{[(1*S*)-2,2,2-trifluoro-1-{4'-(metanosulfonil)-[1,1'-bifenil]-4-il}etil]amino}pentanamida

$C_{25}H_{27}F_4N_3O_3S$



omacetaxini mepesuccinas

omacetaxine mepesuccinate	1-[(1*S*,3a*R*,14b*S*)-2-methoxy-1,5,6,8,9,14b-hexahydro-4*H*-cyclopenta[*a*][1,3]dioxolo[4,5-*h*]pyrrolo[2,1-*b*][3]benzazepin-1-yl] 4-methyl (2*R*)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
mépésuccinate d'omacétaxine	(2*R*)-2-hydroxy-2-(4-hydroxy-4-méthylpentyl)butanedioate de 1-[(1*S*,3a*R*,14b*S*)-2-méthoxy-1,5,6,8,9,14b-hexahydro-4*H*-cyclopenta[*a*][1,3]dioxolo[4,5-*h*]pyrrolo[2,1-*b*][3]benzazépin-1-yle] et de 4-méthyle
mepesuccinato de omacetaxina	(2*R*)-2-hidroxi-2-(4-hidroxi-4-metilpentil)butanodioato de 1-[(1*S*,3a*R*,14b*S*)-2-metoxi-1,5,6,8,9,14b-hexahidro-4*H*-ciclopenta[*a*][1,3]dioxolo[4,5-*h*]pirrolo[2,1-*b*][3]benzazepin-1-ilo] y de 4-metilo

$C_{29}H_{39}NO_9$



otelixizumabum*

otelixizumab — immunoglobulin G1, anti-(human CD3E) humanized/chimeric monoclonal TRX4 (ChAglyCD3); humanized gamma1 heavy chain 299N>A [humanized VH (*Homo sapiens* FR/*Rattus sp.* CDR) (119 residues [8.8.12])- *Homo sapiens* IGHG1*01, 180N>A (CH2 84.4)] (222-216')-disulfide with chimeric lambda light chain 111G>R [*Rattus sp.* V-LAMBDA (110 residues [8.3.9])-*Homo sapiens* IGLC2*01, 1G>R (1.5)] ; (228-228": 231-231")-bisdisulfide dimer

otélixizumab — immunoglobuline G1, anti-(CD3E humain) anticorps monoclonal humanisé/chimérique TRX4 (ChAglyCD3); chaîne lourde gamma1 humanisée 299N>A [VH humanisé (*Homo sapiens* FR/*Rattus sp.* CDR) (119 residus [8.8.12])- *Homo sapiens* IGHG1*01, 180N>A (CH2 84.4) (222-216')-disulfure avec la chaîne lambda chimérique 111G>R [*Rattus sp.* V-LAMBDA (110 residues [8.3.9])-*Homo sapiens* IGLC2*01, 1G>R (1.5)] ; dimère (228-228": 231-231")-bidisulfure

otelixizumab — inmunoglobulina G1, anti-(CD3E humano) anticuerpo monoclonal humanizado/quimérico TRX4 (ChAglyCD3); cadena pesada gamma1 humanizada 299N>A [VH humanizada (*Homo sapiens* FR/*Rattus sp.* CDR) (119 residuos [8.8.12])- *Homo sapiens* IGHG1*01, 180N>A (CH2 84.4) (222-216')-disulfuro con la cadena lambda quimérica 111G>R [*Rattus sp.* V-LAMBDA (110 residuos [8.3.9])-*Homo sapiens* IGLC2*01, 1G>R (1.5)] ; dímero (228-228": 231-231")-bisdisulfuro

$C_{6448}H_{9954}N_{1718}O_{2016}S_{42}$

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG  LVQPGGSLRL  SCAASGFTFS  SFPMAWVRQA  PGKGLEWVST   50
ISTSGGRTYY  RDSVKGRFTI  SRDNSKNTLY  LQMNSLRAED  TAVYYCAKFR  100
QYSGGFDYWG  QGTLVTVSSA  STKGPSVFPL  APSSKSTSGG  TAALGCLVKD  150
YFPEPVTVSW  NSGALTSGVH  TFPAVLQSSG  LYSLSSVVTV  PSSSLGTQTY  200
ICNVNHKPSN  TKVDKKVEPK  SCDKTHTCPP  CPAPELLGGP  SVFLFPPKPK  250
DTLMISRTPE  VTCVVVDVSH  EDPEVKFNWY  VDGVEVHNAK  TKPREEQYAS  300
TYRVVSVLTV  LHQDWLNGKE  YKCKVSNKAL  PAPIEKTISK  AKGQPREPQV  350
YTLPPSRDEL  TKNQVSLTCL  VKGFYPSDIA  VEWESNGQPE  NNYKTTPPVL  400
DSDGSFFLYS  KLTVDKSRWQ  QGNVFSCSVM  HEALHNHYTQ  KSLSLSPGK   449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQPNSV  STSLGSTVKL  SCTLSSGNIE  NNYVHWYQLY  EGRSPTTMIY   50'
DDDKRPDGVP  DRFSGSIDRS  SNSAFLTIHN  VAIEDEAIYF  CHSYVSSFNV  100'
FGGGTKLTVL  RQPKAAPSVT  LFPPSSEELQ  ANKATLVCLI  SDFYPGAVTV  150'
AWKADSSPVK  AGVETTTPSK  QSNNKYAASS  YLSLTPEQWK  SHRSYSCQVT  200'
HEGSTVEKTV  APTECS                                         216'
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
22-96    22"-96"    22'-91'   22"'-91"'  138'-197'  138"'-197"'  146-202  146"-202"
215'-222 215"'-222" 228-228"  231-231"   263-323    263"-323"    369-427  369"-427"
```

pegloticasum*

pegloticase

tetramer α_4 of des-(1-5)-[6-threonine,45-threonine,290-lysine, 300-serine]uricase (EC 1.7.3.3, urate oxidase) from *Sus scrofa* (porcine), non acetylated, of which some of the lysine 6-amine residues are engaged in a carbamate linkage with a monomethylic ether of polyoxyethylene (macrogol)

pégloticase

tétramère α_4 du des-(1-5)-[6-thréonine,45-thréonine,290-lysine, 300-sérine]uricase (EC 1.7.3.3, urate oxydase) de *Sus scrofa* (porc) non acétylé dont certaines fonctions 6-amine de lysines sont engagées dans une liaison carbamate avec un éther monométhylique de polyoxyéthylène (macrogol)

pegloticasa

tetrámero α_4 de la des-(1-5)-[6-treonina,45-treonina,290-lisina, 300-serina]uricasa (EC 1.7.3.3, urato oxidasa) de *Sus scrofa* (porc) no acetilada algunas de cuyas funciones 6-amino de las lisinas forman uniones carbamato con un éter monometílico de polioxietileno (macrogol)

$C_{6196}H_{9720}N_{1632}O_{1792}S_{32}$



H2N-R: Peptide monomer / Peptide monomère / Peptido monómero

```
     TYKKN DEVEFVRTGY GKDMIKVLHI QRDGKYHSIK EVATTVQLTL  50
SSKKDYLHGD NSDVIPTDTI KNTVNVLAKF KGIKSIETFA VTICEHFLSS 100
FKHVIRAQVY VEEVPWKRFE KNGVKHVHAF IYTPTGTHFC EVEQIRNGPP 150
VIHSGIKDLK VLKTTQSGFE GFIKDQFTTL PEVKDRCFAT QVYCKWRYHQ 200
GRDVDFEATW DTVRSIVLQK FAGPYDKGEY SPSVQKTLYD IQVLTLGQVP 250
EIEDMEISLP NIHYLNIDMS KMGLINKEEV LLPLDNPYGK ITGTVKRKLS 300
SRL                                                   303
```

preladenantum

preladenant

2-(furan-2-yl)-7-(2-{4-[4-(2-methoxyethoxy)phenyl]piperazin-1-yl}ethyl)-7*H*-pyrazolo[4,3-*e*][1,2,4]triazolo[1,5-*c*]pyrimidin-5-amine

préladénant

2-(furan-2-yl)-7-(2-{4-[4-(2-méthoxyéthoxy)phényl]pipérazin-1-yl}éthyl)-7*H*-pyrazolo[4,3-*e*][1,2,4]triazolo[1,5-*c*]pyrimidin-5-amine

preladenant

2-(furan-2-il)-7-(2-{4-[4-(2-metoxietoxi)fenil]piperazin-1-il}etil)-7*H*-pirazolo[4,3-*e*][1,2,4]triazolo[1,5-*c*]pirimidin-5-amina

$C_{25}H_{29}N_9O_3$



radiprodilum

radiprodil — 2-{4-[(4-fluorophenyl)methyl]piperidin-1-yl}-2-oxo-*N*-(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)acetamide

radiprodil — 2-{4-[(4-fluorophényl)méthyl]pipéridin-1-yl}-2-oxo-*N*-(2-oxo-2,3-dihydrobenzoxazol-6-yl)acétamide

radiprodil — 2-{4-[(4-fluorofenil)metil]piperidin-1-il}-2-oxo-*N*-(2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)acetamida

$C_{21}H_{20}FN_3O_4$



remogliflozini etabonas

remogliflozin etabonate — 5-methyl-1-(propan-2-yl)-4-({4-[(propan-2-yl)oxy]phenyl}methyl)-1*H*-pyrazol-3-yl 6-*O*-(ethoxycarbonyl)-β-D-glucopyranoside

étabonate de rémogliflozine — 6-*O*-(éthoxycarbonyl)-β-D-glucopyranoside de 5-méthyl-4-{[4-(1-méthyléthoxy)phényl]méthyl}-1-(1-méthyléthyl)-1*H*-pyrazol-3-yle

etabonato de remogliflozina — 6-*O*-(etoxicarbonil)-β-D-glucopiranósido de 5-metil-1-(propan-2-il)-4-({4-[(propan-2-il)oxi]fenil}metil)-1*H*-pirazol-3-ilo

$C_{26}H_{38}N_2O_9$



retosibanum

retosiban — (3*R*,6*R*)-6-[(2*S*)-butan-2-yl]-3-(2,3-dihydro-1*H*-inden-2-yl)-1-[(1*R*)-1-(2-methyl-1,3-oxazol-4-yl)-2-(morpholin-4-yl)-2-oxoethyl]piperazine-2,5-dione

rétosiban — (3*R*,6*R*)-3-(2,3-dihydro-1*H*-indén-2-yl)-1-[(1*R*)-1-(2-méthyloxazol-4-yl)-2-(morpholin-4-yl)-2-oxoéthyl]-6-[(1*S*)-1-méthylpropyl]= pipérazine-2,5-dione

retosibán — (3*R*,6*R*)-6-[(2*S*)-butan-2-il]-3-(2,3-dihidro-1*H*-inden-2-il)-1-[(1*R*)-1-(2-metil-1,3-oxazol-4-il)-2-(morfolin-4-il)-2-oxoetil]piperazina-2,5-diona

$C_{27}H_{34}N_4O_5$



riociguatum

riociguat	methyl *N*-(4,6-diamino-2-{1-[(2-fluorophenyl)methyl]-1*H*-pyrazolo=[3,4-*b*]pyridin-3-yl}pyrimidin-5-yl)-*N*-methylcarbamate
riociguat	(4,6-diamino-2-{1-[(2-fluorophényl)méthyl]-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl}pyrimidin-5-yl)méthylcarbamate de méthyle
riociguat	(4,6-diamino-2-{1-[(2-fluorofenil)metil]-1*H*-pirazolo[3,4-*b*]piridin-3-il}pirimidin-5-il)metilcarbamato de metilo

$C_{20}H_{19}FN_8O_2$



rolofyllinum

rolofylline	1,3-dipropyl-8-(tricyclo[3.3.1.$0^{3,7}$]nonan-3-yl)-3,7-dihydro-1*H*-purin-2,6-dione
rolofylline	1,3-dipropyl-8-(tricyclo[3.3.1.$0^{3,7}$]non-3-yl)-3,7-dihydro-1*H*-purine-2,6-dione
rolofyllina	1,3-dipropil-8-(triciclo[3.3.1.$0^{3,7}$]nonan-3-il)-3,7-dihidro-1*H*-purina-2,6-diona

$C_{20}H_{28}N_4O_2$



tenatumomabum*

tenatumomab — immunoglobulin G2b, anti-[human tenascin C (TNC, hexabrachion, HBX) *Mus musculus*] monoclonal antibody ST2146; gamma2b heavy chain (*Mus musculus* VH [8.8.13]-IGHG2B*02 from clone ST2146) (135-219')-disulfide with kappa light chain (*Mus musculus* V-KAPPA [11.3.9]-IGKC*01 from clone ST 2146); (229-229'':232-232'':235-235'':238-238'')-tetradisulfide dimer

ténatumomab — immunoglobuline G2b, anti-[tenascine C humaine (TNC, hexabrachion, HBX) *Mus musculus*] anticorps monoclonal murin ST2146; chaîne lourde gamma2b (*Mus musculus* VH [8.8.13]-IGHG2B*02 du clone ST2146) (135-219')-disulfure avec la chaîne légère kappa (*Mus musculus* V-KAPPA [11.3.9]-IGKC*01 du clone ST 2146); dimère (229-229'':232-232'':235-235'':238-238'')-tétradisulfide

tenatumomab — inmunoglobulina G2b, anti-[tenascina C humana (TNC, hexabrachion, HBX) *Mus musculus*] anticuerpo monoclonal murino ST2146; cadena pesada gamma2b (*Mus musculus* VH [8.8.13]-IGHG2B*02 del clon ST2146) (135-219')-disulfuro con la cadena ligera kappa (*Mus musculus* V-KAPPA [11.3.9]-IGKC*01 del clon ST 2146); dímero (229-229'':232-232'':235-235'':238-238'')-tetradisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EIQLQQSGPE LVKPGASVKV SCKASGYAFT SYNMYWVKQS HGKSLEWIGY  50
IDPYNGVTSY NQKFKGKATL TVDKSSSTAY MHLNSLTSED SAVYYCARGG 100
GSIYYAMDYW GQGTSVTVSS AKTTPPSVYP LAPGCGDTTG SSVTLGCLVK 150
GYFPESVTVT WNSGSLSSSV HTFPALLQSG LYTMSSSVTV PSSTWPSQTV 200
TCSVAHPASS TTVDKKLEPS GPISTINPCP PCKECHKCPA PNLEGGPSVF 250
IFPPNIKDVL MISLTPKVTC VVVDVSEDDP DVQISWFVNN VEVHTAQTQT 300
HREDYNSTIR VVSTLPIQHQ DWMSGKEFKC KVNNKDLPSP IERTISKIKG 350
LVRAPQVYIL PPPAEQLSRK DVSLTCLVVG FNPGDISVEW TSNGHTEENY 400
KDTAPVLDSD GSYFIYSKLN MKTSKWEKTD SFSCNVRHEG LKNYYLKKTI 450
SRSPGK                                                  456
```

Light chain/ Chaîne légère / Cadena ligera

```
DIVMTQAAPS VPVTPGESVS ISCRSSKSLL HSNGNTYLYW FLQRPGQSPQ  50
LLIYRMSNLA SGVPDRFSGS GSGTAFTLRI SRVEAEDVGV YYCMQHLEYP 100
LTFGAGTKLE LKRADAAPTV SIFPPSSEQL TSGGASVVCF LNNFYPKDIN 150
VKWKIDGSER QNGVLNSWTD QDSKDSTYSM SSTLTLTKDE YERHNSYTCE 200
ATHKTSTSPI VKSFNRNEC                                    219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Bold and underlined **Cysteins** are those involved in disulphide bridges.

tertomotidum

tertomotide — human telomerase reverse transcriptase (EC 2.7.7.49)-(611-626)-peptide (telomerase catalytic subunit fragment)

tertomotide — télomérase transcriptase réverse humaine (EC 2.7.7.49)-(611-626)-peptide (fragment de la sous-unité catalytique de la télomérase)

tertomotida — transcriptasa inversa humana telomerasa (EC 2.7.7.49)-(611-626)-péptido (fragmento de la subunidad catalítica de la telomerasa

$C_{85}H_{146}N_{26}O_{21}$

H-Glu—Ala—Arg—Pro—Ala—Leu—Leu—Thr—Ser—

Arg—Leu—Arg—Phe—Ile—Pro—Lys-OH

10 16

tigatuzumabum*

tigatuzumab — immunoglobulin G1, anti-[*Homo sapiens* TNFRSF10B (tumor necrosis factor receptor superfamily member 10b, DR5, TRAIL-R2, CD262)] humanized monoclonal TRA-8 (or CS-1008); gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.12] -*Homo sapiens* IGHG1*03] (222-213')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR) [6.3.8] -*Homo sapiens* IGKC*01]; (228-228":231-231")-bisdisulfide dimer

tigatuzumab — mmunoglobuline G1, anti-[*Homo sapiens* TNFRSF10B (membre 10b de la superfamille des récepteurs du facteur de nécrose tumorale, DR5, TRAIL-R2, CD262)] anticorps monoclonal humanisé TRA-8 (ou CS-1008); chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.12] - *Homo sapiens* IGHG1*03] (222-213')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [6.3.8] -*Homo sapiens* IGKC*01]; dimère (228-228":231-231")-bisdisulfure

tigatuzumab — inmunoglobulina G1, anti-[*Homo sapiens* TNFRSF10B (miembro 10b de la superfamilia de receptores del factor de necrosis tumoral, DR5, TRAIL-R2, CD262)] anticuerpo monoclonal humanizado TRA-8 (o CS-1008); cadena pesada gamma1 [VH humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.12] - *Homo sapiens* IGHG1*03] (222-213')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [6.3.8] -*Homo sapiens* IGKC*01]; dímero (228-228":231-231")-bisdisulfuro

$C_{6406}H_{9924}N_{1716}O_{2012}S_{46}$

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG  LVQPGGSLRL  SCAASGFTFS  SYVMSWVRQA  PGKGLEWVAT   50
ISSGGSYTYY  PDSVKGRFTI  SRDNAKNTLY  LQMNSLRAED  TAVYYCARRG  100
DSMITTDYWG  QGTLVTVSSA  STKGPSVFPL  APSSKSTSGG  TAALGCLVKD  150
YFPEPVTVSW  NSGALTSGVH  TFPAVLQSSG  LYSLSSVVTV  PSSSLGTQTY  200
ICNVNHKPSN  TKVDKRVEPK  SCDKTHTCPP  CPAPELLGGP  SVFLFPPKPK  250
DTLMISRTPE  VTCVVVDVSH  EDPEVKFNWY  VDGVEVHNAK  TKPREEQYNS  300
TYRVVSVLTV  LHQDWLNGKE  YKCKVSNKAL  PAPIEKTISK  AKGQPREPQV  350
YTLPPSREEM  TKNQVSLTCL  VKGFYPSDIA  VEWESNGQPE  NNYKTTPPVL  400
DSDGSFFLYS  KLTVDKSRWQ  QGNVFSCSVM  HEALHNHYTQ  KSLSLSPGK   449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS  LSASVGDRVT  ITCKASQDVG  TAVAWYQQKP  GKAPKLLIYW  50'
ASTRHTGVPS  RFSGSGSGTD  FTLTISSLQP  EDFATYYCQQ  YSSYRTFGQG  100'
TKVEIKRTVA  APSVFIFPPS  DEQLKSGTAS  VVCLLNNFYP  REAKVQWKVD  150'
NALQSGNSQE  SVTEQDSKDS  TYSLSSTLTL  SKADYEKHKV  YACEVTHQGL  200'
SSPVTKSFNR  GEC         213'
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96 22"-96" 23'-88' 23'"-88'" 133'-193' 133'"-193'" 146-202 146"-202" 213'-222 213'"-222" 228-228" 231-231" 263-323 263"-323" 369-427 369"-427"

velaglucerasum alfa*

velaglucerase alfa — human glucosylceramidase (EC 3.2.1.45 or beta-glucocerebrosidase), glycoform α

vélaglucérase alfa — glucosylcéramidase humaine (EC 3.2.1.45 ou bêta-glucocérébrosidase), glycoform α

velaglucerasa alfa — glucosilceramidasa humana (EC 3.2.1.45 o beta-glucocerebrosidasa), glicoforma α

$C_{2532}H_{3850}N_{672}O_{711}S_{16}$

```
ARPCIPKSFG  YSSVVCVCNA  TYCDSFDPPT  FPALGTFSRY  ESTRSGRRME   50
LSMGPIQANH  TGTGLLLTLQ  PEQKFQKVKG  FGGAMTDAAA  LNILALSPPA  100
QNLLLKSYFS  EEGIGYNIIR  VPMASCDFSI  RTYTYADTPD  DFQLHNFSLP  150
EEDTKLKIPL  IHRALQLAQR  PVSLLASPWT  SPTWLKTNGA  VNGKGSLKGQ  200
PGDIYHQTWA  RYFVKFLDAY  AEHKLQFWAV  TAENEPSAGL  LSGYPFQCLG  250
FTPEHQRDFI  ARDLGPTLAN  STHHNVRLLM  LDDQRLLLPH  WAKVVLTDPE  300
AAKYVHGIAV  HWYLDFLAPA  KATLGETHRL  FPNTMLFASE  ACVGSKFWEQ  350
SVRLGSWDRG  MQYSHSIITN  LLYHVVGWTD  WNLALNPEGG  PNWVRNFVDS  400
PIIVDITKDT  FYKQPMFYHL  GHFSKFIPEG  SQRVGLVASQ  KNDLDAVALM  450
HPDGSAVVVV  LNRSSKDVPL  TIKDPAVGFL  ETISPGYSIH  TYLWRRQ     497
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
4-16 18-23

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
Asn-19 Asn-59 Asn-146 Asn-270 Asn-462

veltuzumabum*
veltuzumab

immunoglobulin G1, anti-[*Homo sapiens* CD20 (MS4A1, membrane-spanning 4-domains subfamily A member 1, B lymphocyte surface antigen B1, Leu-16, Bp35)] humanized monoclonal IMMU-106 (or hA20); gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.14] -*Homo sapiens* IGHG1*03] (224-213')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR) [5.3.9] -*Homo sapiens* IGKC*01]; (230-230":233-233")-bisdisulfide dimer

veltuzumab

immunoglobuline G1, anti-[*Homo sapiens* CD20 (MS4A1, membre 1 de la sous-famille A à 4 domaines transmembranaires, antigène de surface B1 des lymphocytes B, Leu-16, Bp35)] anticorps monoclonal humanisé IMMU-106 (ou hA20); chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.14] - *Homo sapiens* IGHG1*03] (224-213')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [5.3.9] -*Homo sapiens* IGKC*01]; dimère (230-230":233-233")-bisdisulfure

veltuzumab

inmunoglobulina G1, anti-[*Homo sapiens* CD20 (MS4A1, miembro 1 de la subfamilia A con 4 dominios transmembranarios , antígeno de superficie B1 de los linfocitos B, Leu-16, Bp35)] anticuerpo monoclonal humanizado IMMU-106 (ou hA20); cadena pesada gamma1 [VH humanizado (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.14] - *Homo sapiens* IGHG1*03] (224-213')-disulfuro con la cadena ligera kappa [V-KAPPA humanizado (*Homo sapiens* FR/*Mus musculus* CDR) [5.3.9] -*Homo sapiens* IGKC*01]; dímero (230-230":233-233")-bisdisulfuro

$C_{6458}H_{9918}N_{1706}O_{2026}S_{46}$

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGAE  VKKPGSSVKV  SCKASGYTFT  SYNMHWVKQA  PGQGLEWIGA   50
IYPGMGDTSY  NQKFKGKATL  TADESTNTAY  MELSSLRSED  TAFYYCARST  100
YYGGDWYFDV  WGQGTTVTVS  SASTKGPSVF  PLAPSSKSTS  GGTAALGCLV  150
KDYFPEPVTV  SWNSGALTSG  VHTFPAVLQS  SGLYSLSSVV  TVPSSSLGTQ  200
TYICNVNHKP  SNTKVDKRVE  PKSCDKTHTC  PPCPAPELLG  GPSVFLFPPK  250
PKDTLMISRT  PEVTCVVVDV  SHEDPEVKFN  WYVDGVEVHN  AKTKPREEQY  300
NSTYRVVSVL  TVLHQDWLNG  KEYKCKVSNK  ALPAPIEKTI  SKAKGQPREP  350
QVYTLPPSRE  EMTKNQVSLT  CLVKGFYPSD  IAVEWESNGQ  PENNYKTTPP  400
VLDSDGSFFL  YSKLTVDKSR  WQQGNVFSCS  VMHEALHNHY  TQKSLSLSPG  450
K                                                          451
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPSS  LSASVGDRVT  MTCRASSSVS  YIHWFQQKPG  KAPKPWIYAT   50'
SNLASGVPVR  FSGSGSGTDY  TFTISSLQPE  DIATYYCQQW  TSNPPTFGGG  100'
TKLEIKRTVA  APSVFIFPPS  DEQLKSGTAS  VVCLLNNFYP  REAKVQWKVD  150'
NALQSGNSQE  SVTEQDSKDS  TYSLSSTLTL  SKADYEKHKV  YACEVTHQGL  200'
SSPVTKSFNR  GEC                                            213'
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
22-96    22"-96"    23'-87'    23'"-87'"   133'-193'  133'"-193'"  148'-204  148"-204"
213'-224 213'"-224" 230-230"   233-233"    265-325    265"-325"    371-429   371"-429"
```

viquidacinum

viquidacin (3*R*,4*R*)-4-{(3*S*)-3-[3-fluoro-6-methoxyquinolin-4-yl]-3-hydroxypropyl}-1-{2-[(thiophen-2-yl)sulfanyl]ethyl}piperidine-3-carboxylic acid

viquidacine acide (3*R*,4*R*)-4-[(3*S*)-3-(3-fluoro-6-méthoxyquinoléin-4-yl)-3-hydroxypropyl]-1-[2-(thiophén-2-ylsulfanyl)éthyl]pipéridine-3-carboxylique

viquidacina ácido (3*R*,4*R*)-4-{(3*S*)-3-[3-fluoro-6-metoxiquinolin-4-il]-3-hidroxipropil}-1-{2-[(tiofen-2-il)sulfanil]etil}piperidina-3-carboxílico

$C_{25}H_{29}FN_2O_4S_2$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 59
Dénominations communes internationales recommandées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 22, No. 1, 2008)

p. 43	*suprimáse* albinterferón alfa2b	*insertése* albinterferón alfa-2b
p. 48	*supprimer* céftaroline fosamil	*insérer* ceftaroline fosamil

* Electronic structure available on Mednet: http://mednet.who.int/
* Structure électronique disponible sur Mednet: http://mednet.who.int/
* Estructura electrónica disponible en Mednet: http://mednet.who.int/

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.